Clindamycin Phosphate

DRUG5 trials

Sponsors

Hadassah Medical Organization, Lumara Health, Inc., Sun Pharmaceutical Industries, Inc., Memorial Sloan Kettering Cancer Center, Ain Shams Maternity Hospital

Conditions

Acne VulgarisBacterial VaginosisGlioblastomaRecurrent GlioblastomaSkin ToxicityVaginitisVulvovaginitis

Phase 1

Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris

CompletedNCT00361322

Hadassah Medical OrganizationAcne Vulgaris

Start: 2005-04-30End: 2006-01-31Target: 40Updated: 2006-08-08

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

CompletedNCT04321070

Sun Pharmaceutical Industries, Inc.Acne Vulgaris

Start: 2019-09-09End: 2020-03-06Updated: 2025-04-10

Phase 2

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Active, not recruitingNCT04469075

Memorial Sloan Kettering Cancer CenterGlioblastoma, Recurrent Glioblastoma, Skin Toxicity

Start: 2020-07-09End: 2027-07-01Updated: 2026-08-10

Phase 3

Vaginal Infection Study

CompletedNCT00616330

Lumara Health, Inc.Vaginitis, Vulvovaginitis

Start: 2008-01-31End: 2009-12-31Updated: 2012-03-05

Unknown Phase

Title of the Protocol: Combined Use of Vaginal Clindamycin Cream and Oral Metronidazole Versus Oral Metronidazole

CompletedNCT07247851

Ain Shams Maternity HospitalBacterial Vaginosis

Start: 2024-01-10End: 2024-06-10Updated: 2025-11-25

Related Papers

The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields.

Journal of Clinical Oncology2022-06-01